Immunotherapy in Small Cell Lung Cancer

Small-cell lung cancer (SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2020-09, Vol.12 (9), p.2522
Hauptverfasser:	Esposito, Giovanna, Palumbo, Giuliano, Carillio, Guido, Manzo, Anna, Montanino, Agnese, Sforza, Vincenzo, Costanzo, Raffaele, Sandomenico, Claudia, La Manna, Carmine, Martucci, Nicola, La Rocca, Antonello, De Luca, Giuseppe, Piccirillo, Maria Carmela, De Cecio, Rossella, Botti, Gerardo, Totaro, Giuseppe, Muto, Paolo, Picone, Carmine, Normanno, Nicola, Morabito, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Antitumor agents Cancer therapies Care and treatment Chemotherapy Clinical trials Cytotoxicity Etoposide FDA approval Histology Immune checkpoint inhibitors Immune system Immunotherapy Ligands Lung cancer Lymphocytes Metastasis Monoclonal antibodies Mutation Patient outcomes Pembrolizumab Platinum Radiation therapy Review Safety Small cell lung cancer Small cell lung carcinoma Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!